London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Stick with us here Sharehunter. You've seen all the research, you even contribute to it. NCYT is the BEST play on AIM right now, maybe ever!! Hold tight to your shares and add when/if you can!
Sharehunter, you've been here a long time and through the ups and downs. This share has a long way to go IMO. Big players like Numis are bring their customers onboard and they have a reputation to keep.
Hey guys,
We've made a correction to today's article on the PE ratio.
Currently Novacyt's cap is around £700 million and projected revenues for the 12 months ahead are expected to be greater than that. The article didn't reflect that correctly and has been amended with a less forward looking range of 2020 Year End forecasts from 200 million to 450 million. That should be easier to come to terms with, and when we have a little more info we can do something more interesting speculatively for 2021.
A lot for this year depends on how much of the two tenders around £468 million in total, announced by the government are actually for 2020 and will be paid within Q4.
The ranges do not account for any new large government contracts in other areas as that's entirely speculative, but would changes things significantly.
Hopefully Q3 results will be published shortly and that will give us a more information to work with. Everyone's waiting for that now, not just us private investors, but institutions also. It will make all the difference having those numbers and unlock Novacyt's potential going ahead. The other issue is that the recent government tenders may not be included in Q3, but we would still get a good look at how sales have been increasing month on month over the summer, and perhaps even some WinterPlex orders from September.
Ok so it's ade's analysis against tayq's analysis which will it be erm erm erm
It was tough but Tayq for me.
I picked up on the fact that they've only done half year results in the past. To move from half year to quarterly results, is it purely an internal decision or are there some regulatory things to account for?
Ebv they went monthly for a couple so nothing since June they are not obliged just some people hoping, set against that you don't want your buy out targets seeing how heavy your saddle bags are as you walk into the bar.
@EBV @Wilson
Apparently it's now a game of cat and mouse with institutional investors. Novacyt's board is frustrated from what I'm told on the poor institutional investment so far (hence you've seen them go all in with 3 brokerages, all with various clients and research resources).
The problem goes back quite a long way. The last time any research was done on Novacyt was April 2017 by Edison:
https://postimg.cc/Wdb79RSS
So now we only have NUMIS who to our knowledge have published institutional research. NUMIS have of course forced Novacyt's hand here with figures that I'm sure the CEO isn't too pleased with. When companies perform, they would like to see that performance reflected in forecasts. It is only for this reason that there's speculation Novacyt will publish Q3 figures.
It's a rare occasion that PI's are ahead of the game, we're all likely have much better holdings than funds buying in lately. Many institutions still do not know Novacyt's name. There's a lot of movement to look forward to in 2021, but these things do take time and Novacyt apparently share our frustrations. They hold the key though, Q3. Why not use it.
Did NCYT actually decline investment a few months back, or were they just too busy to sit down and talk outside investment at that time?
Yes it was mentioned in an RNS, Graham was approached but he didn't want to do any further placings for II's and told them to buy on open market.
@Louis
No idea Louis, but there is something really interesting regarding an old investor there. That's for the French guys to finish looking into and will be known late October. Problem is we have no share register so there's a lot of caution when it comes to naming who's has been buying Novacyt.
I have a big mouth too so that doesn't help when getting info either! But yes, something interesting shortly on a fund, think the French guys just want to confirm before putting it out there.
Thanks for the reply. Sounds promising!
I'll root through the RNSs to see where outside investment got mentioned. It was about 3 or 4 months back, from memory.